Lung cancer chemotherapy
Lung cancer occurs when there is an unusual growth of cells in the lung tissue growth, usually malignant, metastasis and proliferation may lead to other body tissues. This type of cancer is divided by the size and appearance of cells: small cell lung cancer and small cell.
The most common symptoms are usually shortness of breath, cough, including coughing up blood, weight loss, chest pain, hoarseness and swelling in the neck and face, among others.
The most common cause of lung cancer is smoking and people who do not have this habit, the development of cancer is usually a result of genetic factors and exposure to radon (chemical element), asbestos (fibrous metamorphic mineral), and pollution air pollution, including secondhand smoke (passive smoking).
Among the treatment options for lung cancer non-small cell, which is the most common type (it is estimated that approximately 80% of cases, as shown on page www.info.cancerresearchuk.org) AstraZeneca developed a molecular therapy with major advantages over chemotherapy.
Recently, the molecule Gefitinib proved as effective as chemotherapy most widely used second-line treatment with the advantage that produces no side-effects of these therapies such as general deterioration of the patient, nausea, vomiting, hair loss and decrease in white blood cells, causing a predisposition to infection.
The molecule Gefitinib does give better quality of life for the patient with lung cancer and is considered a “treatment directed”, ie that its mechanism of action operates directly on cancer cells without affecting the proper functioning of the organism, preventing the spread of the disease and related mechanisms that blocks the growth, proliferation and spread of cancer. It also has a simple oral administration which facilitates the adherence by the patient to cancer treatment.
It is vital that the individual together with a physician to explore all available alternatives for the treatment of this disease and help make a better choice for that cancer does not thrive without affecting the quality of life of patients.